Artificial Tears Study in Mild to Moderate Dry Eye Patients

Abbott

Status and phase: Completed; Phase 2

Conditions: Dry Eye

Treatments: Drug: Systane; Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Study type: Interventional

Funder types: Industry

Identifiers

NCT00607776

PEGT-104-9582

Details and patient eligibility

About

The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Mild to moderate dry eye
• over 18

Exclusion criteria

• No concurrent ocular disease or meds

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

110 participants in 2 patient groups

1

Active Comparator group

Description:

Systane

Treatment:

Drug: Systane

2

Experimental group

Description:

Blink tears

Treatment:

Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400